Literature DB >> 16178015

Pathways mediating abnormal intracortical inhibition in Parkinson's disease.

Colum D MacKinnon1, Emily A Gilley, Annette Weis-McNulty, Tanya Simuni.   

Abstract

Previous studies have used paired-pulse transcranial magnetic stimulation to show that short-interval intracortical inhibition (SICI) is reduced in patients with Parkinson's disease (PD). This study examined whether reduced SICI in PD is caused by an increase in the threshold of inhibitory pathways or a reduction in the threshold of excitatory pathways. Motor-evoked potentials were recorded from a hand muscle in 12 patients with PD (7 patients were tested off and on antiparkinsonian medications) and 12 control subjects. SICI was tested at seven conditioning stimulus intensities (CSIs; 40-100% of resting motor threshold) and at interstimulus intervals (ISIs) of 2, 3, and 4 milliseconds. No differences were found between groups in resting or active motor threshold, SICI threshold, or the extent of SICI at CSIs at or below 80% of resting motor threshold. Significant differences between groups were observed at CSIs of 90% and 100% with an ISI of 3 milliseconds. Antiparkinsonian medication had no effect on SICI. These findings show that the low threshold inhibitory pathways mediating SICI are normal in PD. The suppression of SICI observed at higher CSIs suggests that the threshold of intracortical facilitatory pathways is decreased in PD.

Entities:  

Mesh:

Year:  2005        PMID: 16178015     DOI: 10.1002/ana.20599

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  25 in total

1.  Age-related changes in short-latency motor cortex inhibition.

Authors:  Ashleigh E Smith; Michael C Ridding; Ryan D Higgins; Gary A Wittert; Julia B Pitcher
Journal:  Exp Brain Res       Date:  2009-07-19       Impact factor: 1.972

2.  Aberrant cortical excitability reflects the loss of hand dexterity in musician's dystonia.

Authors:  Shinichi Furuya; Kazumasa Uehara; Takashi Sakamoto; Takashi Hanakawa
Journal:  J Physiol       Date:  2018-04-25       Impact factor: 5.182

Review 3.  Effects of deep brain stimulation on the primary motor cortex: Insights from transcranial magnetic stimulation studies.

Authors:  Zhen Ni; Kaviraja Udupa; Mark Hallett; Robert Chen
Journal:  Clin Neurophysiol       Date:  2018-11-30       Impact factor: 3.708

4.  Reward processing abnormalities in Parkinson's disease.

Authors:  Dimitrios Kapogiannis; Eric Mooshagian; Paul Campion; Jordan Grafman; Trelawny J Zimmermann; Kelsey C Ladt; Eric M Wassermann
Journal:  Mov Disord       Date:  2011-04-29       Impact factor: 10.338

Review 5.  Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease.

Authors:  Steve Vucic; Matthew C Kiernan
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

6.  Evidence for normal intracortical inhibitory recruitment properties in cervical dystonia.

Authors:  Rebekah L S Summers; Mo Chen; Colum D MacKinnon; Teresa J Kimberley
Journal:  Clin Neurophysiol       Date:  2020-04-02       Impact factor: 3.708

7.  Short-interval intracortical inhibition in Parkinson's disease using anterior-posterior directed currents.

Authors:  R Hanajima; Y Terao; Y Shirota; S Ohminami; S Nakatani-Enomoto; S Okabe; H Matsumoto; R Tsutsumi; Y Ugawa
Journal:  Exp Brain Res       Date:  2011-08-13       Impact factor: 1.972

Review 8.  Safety of transcranial magnetic stimulation in Parkinson's disease: a review of the literature.

Authors:  Matthew Vonloh; Robert Chen; Benzi Kluger
Journal:  Parkinsonism Relat Disord       Date:  2013-03-07       Impact factor: 4.891

9.  Short interval intracortical inhibition and facilitation during the silent period in human.

Authors:  Zhen Ni; Carolyn Gunraj; Robert Chen
Journal:  J Physiol       Date:  2007-07-26       Impact factor: 5.182

10.  Reward-related activity in the human motor cortex.

Authors:  Dimitrios Kapogiannis; Paul Campion; Jordan Grafman; Eric M Wassermann
Journal:  Eur J Neurosci       Date:  2008-03-25       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.